Axel Ullrich, Munich DE
Axel Ullrich, Munich DE
Patent application number | Description | Published |
---|---|---|
20110008347 | CANCER-RELATED PROTEIN KINASES - The present invention relates to mutant kinase polypeptides and kinase variants selected from the group consisting of AATYK (AATK), ABL1, ACK1, ALK, ARG, AXL, BMX, BRK, BTK, CCK4, CSFR1, CSK, DDR1, DDR2, EGFR, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA10, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, FAK, FER, FES, FGFR1, FGFR2, FGFR4, FLT3, FRK, FYN, HER2, HER3, HER4, IGF1R, INSR, ITK, JAK1, JAK2, JAK3, LCK, LMTK2 (AATYK2/BREK), LYN, MATK, MER, MET, NTRK1, NTRK2, NTRK3, PDGRFA, PDGFRB, PTK-9, PYK2, RET, RON, ROR1, ROR2, ROS, RYK, STYK, SYK, TEC, TEK, TIE, TNK1, TXK, TYK2, TYRO3, VEGFR1, VEGFR2, VEGFR3, YES1, and ZAP70, nucleotide sequences encoding the mutant kinase polypeptides and kinase variants, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions, including the screening for and identification of novel protein kinase modulators. | 01-13-2011 |
20110033482 | HER3 AS A DETERMINANT FOR THE PROGNOSIS OF MELANOMA - Disclosed are inhibitors of HER3 for the treatment of melanoma, in particular melanoma metastases and/or refractory melanoma, pharmaceutical compositions comprising such an inhibitor and a method for the diagnosis or prognosis of melanoma. | 02-10-2011 |
20110179505 | RODENT CANCER MODEL FOR HUMAN FGFR4 ARG388 POLYMORPHISM - The present invention provides a rodent animal for studying the molecular mechanisms and physiological processes associated with uncontrolled cell growth, e.g. cancer, and with a modified FGFR4. | 07-21-2011 |
20120277231 | QUINOLINYLOXYPHENYLSULFONAMIDES - The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases. | 11-01-2012 |
20130084300 | DIAGNOSIS AND PREVENTION OF CANCER CELL INVASION - The present invention relates to diagnostic and therapeutic methods in the field of malignant disorders. More particularly, the invention provides methods of determining the invasivity of malignant disorders and methods for reducing the invasivity of malignant disorders including the prevention or treatment of cancer cell invasion. | 04-04-2013 |
20130336986 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY - The present invention is related to compound capable of modulating the activity and/or expression of the protein kinases SCYL1, ADCK1, and GRK5, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of diseases of the carbohydrate metabolism. The invention is further related to methods of treatment of diseases of the carbohydrate metabolism, particularly diabetes mellitus type 2. | 12-19-2013 |
20140018365 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS - The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof. | 01-16-2014 |
20140336191 | QUINOLINYLOXYPHENYLSULFONAMIDES - The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases. | 11-13-2014 |
20150079108 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY - The present invention is related to compound capable of modulating the activity and/or expression of the protein kinase GRK5, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of diseases of the carbohydrate metabolism. The invention is further related to methods of treatment of diseases of the carbohydrate metabolism, particularly diabetes mellitus type 2. | 03-19-2015 |